ERBB2 and breast carcinoma: HER2-positive breast cancer (HER2+ BC), which represents about 25–30% of breast cancers, is characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2/neu), a tyrosine kinase receptor (RTK).